登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002382 证券简称：蓝帆医疗 公告编号：2026-014 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 第六届董事会第三十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十九次会议于2026年2月14日以电子邮件 的方式发出通知，于2026年2月24日以通讯表决的方式召开。本次会议应参加会议董事8人，实际参加会 议董事8人，全体董事以通讯的方式出席会议。公司董事长刘文静女士主持了本次会议。会议的通知、 召开、表决程序符合《中华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； 截至2026年2月24日，公司股票已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股 价格85%的情形，已触发"蓝帆转债"转股价格向下修正条件。 为充分保护债券持有人利益，优化公司资本结构，支持公 ...

Group 1 - Jianlong Micro-Nano plans to reduce its shareholding by no more than 2% [1] - Meinuohua expects a full-year profit of 100 million to 123 million in 2025, representing a year-on-year growth of 49.69% to 84.11% [1] - Qixiang Tengda anticipates a full-year loss of 660 million to 470 million in 2025 [1] Group 2 - Aojia Convertible Bond and Huahai Convertible Bond will not undergo adjustments [1] - The proposed adjustment for Longda Convertible Bond is scheduled for January 27, 2026 [1] - Various convertible bonds have specific details regarding their current prices, redemption prices, last trading dates, and conversion values [4][6]

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 曾健辉） 每经AI快讯，蓝帆医疗1月26日晚间发布公告称，公司第六届第三十八次董事会会议于2026年1月26日 在公司第一会议室以现场及通讯表决相结合的方式召开。会议审议了《关于向下修正"蓝帆转债"转股价 格的议案》等文件。 ...

Group 1 - The core point of the news is that Bluestar Medical (002382) is proposing to lower the conversion price of its convertible bonds due to the stock price being below the required threshold for a certain period [1][2][4] - On January 8, 2026, Bluestar Medical's stock closed at 5.86 yuan, with a 1.21% increase, a turnover rate of 1.43%, a trading volume of 142,500 shares, and a transaction amount of 83.22 million yuan [1] - The company reported a net outflow of 285.43 million yuan from institutional investors and a net inflow of 432.3 million yuan from retail investors on January 8 [1][4] Group 2 - The Board of Directors of Bluestar Medical approved a proposal to lower the conversion price of the "Bluestar Convertible Bonds" due to the stock price being below 85% of the conversion price for at least 15 out of the last 30 trading days [1][2] - The proposed adjustment to the conversion price will be submitted for approval at the first extraordinary general meeting of shareholders in 2026, scheduled for January 26, 2026 [2] - The adjustment must be approved by more than two-thirds of the voting rights held by shareholders present at the meeting, and bondholders must abstain from voting [2]

Group 1 - The company held its 37th meeting of the sixth board of directors on January 7, 2026, via electronic communication, with all 8 directors participating [2][5] - The board proposed to lower the conversion price of the "Blue Sail Convertible Bond" due to the stock price being below 85% of the conversion price for at least 15 out of the last 30 trading days, triggering the condition for price adjustment [3][31][46] - The proposed adjustment will be submitted to the shareholders' meeting for approval, and the new conversion price must not be lower than the higher of the average stock price over the last 20 trading days before the meeting and the last trading day's price, as well as not lower than the latest audited net asset value per share and the par value [3][46] Group 2 - The company decided to hold its first extraordinary shareholders' meeting of 2026 on January 26, 2026, to discuss the proposed adjustment of the convertible bond conversion price [6][7] - The meeting will be conducted both in-person and via online voting, with specific time slots for voting provided [13][19] - Shareholders holding the convertible bonds must abstain from voting on the proposal to adjust the conversion price, which requires a two-thirds majority approval from the attending shareholders [15][46]

Group 1 - The company held its 37th meeting of the sixth board of directors on January 7, 2026, via electronic communication, with all 8 directors participating [2][3]. - The board proposed to lower the conversion price of the "Blue Sail Convertible Bond" due to the stock price being below 85% of the current conversion price for at least 15 out of the last 30 trading days [3][12][28]. - The proposed adjustment to the conversion price requires approval from the shareholders' meeting, and the new price must not be lower than the higher of the average stock price over the last 20 trading days before the meeting or the latest audited net asset value per share [3][28]. Group 2 - The company plans to hold its first extraordinary shareholders' meeting of 2026 on January 26, 2026, to discuss the proposed adjustment to the bond conversion price [6][7][32]. - The meeting will be conducted both in-person and via online voting, with specific time slots for voting outlined [34][45]. - Shareholders holding the convertible bonds must abstain from voting on the proposal to adjust the conversion price [40].

Group 1 - The core viewpoint of the articles revolves around recent corporate actions and updates regarding convertible bonds and shareholder activities [1][2][9]. Group 2 - Shareholder Sunshine Life intends to reduce its stake in Huakang Clean by no more than 3% [1]. - Baichuan Changyin's controlling shareholder plans to provide a financial support of up to RMB 48 million without interest or collateral to support the company's operational needs [1]. Group 3 - The last trading day for Liuyao convertible bonds is set for January 12, 2026 [2]. - Various convertible bonds are listed with their respective details, including their current prices, redemption prices, last trading days, and conversion values [3][5][7]. - Specific convertible bonds such as Huanxu Convertible Bond is subject to strong redemption, while Lanfan Convertible Bond proposes a down adjustment [9].

Group 1 - The company, Bluestar Medical, announced that its sixth board of directors held the thirty-seventh meeting, where it approved the proposal to lower the conversion price of "Bluestar Convertible Bonds" [2] - The board also approved the proposal to convene the first extraordinary shareholders' meeting of 2026 [2]

Group 1 - The company plans to apply for a total credit limit of up to RMB 3 billion for 2026, which includes various types of financing such as working capital loans and guarantees [2] - The company will provide guarantees for its subsidiaries, with a maximum guarantee amount of RMB 2.8 billion for subsidiaries with a debt-to-asset ratio below 70% and RMB 200 million for those at or above 70% [2] - The guarantees will be valid for 12 months from the date of the shareholders' meeting resolution [2] Group 2 - The company's wholly-owned subsidiary, Shandong Lanfang New Materials Co., Ltd., has applied for a one-year loan from Industrial Bank Co., Ltd., and the company has signed a maximum guarantee contract for this loan [4] - The total amount of guarantees provided will not exceed the approved limit from the shareholders' meeting, thus no additional board or shareholder meetings are required [4] - As of the announcement date, the total guarantee amount for the company and its subsidiaries is RMB 3,539.33 million, which accounts for 43.23% of the company's audited net assets for 2024 [9] Group 3 - The company issued a total of 31,440,400 convertible bonds, with a total issuance amount of RMB 314.404 million [13] - In the fourth quarter of 2025, the company saw a reduction of RMB 61,000 in convertible bonds due to conversion, resulting in an increase of 5,957 shares [17] - The total balance of convertible bonds as of December 31, 2025, is RMB 1,520,378,200 [17]

Core Viewpoint - The company, Bluestar Medical (002382), will comply with the scheduled disclosure of its annual report and will conduct impairment tests and goodwill assessments at the end of each reporting period [1] Group 1: Financial Reporting and Compliance - The company will have professional accounting and evaluation institutions audit and assess the performance commitments and goodwill impairment situations [1] - The company has triggered the conditions for the adjustment of the conversion price of Bluestar convertible bonds multiple times, and the conversion price has been adjusted to 9.50 yuan per share [1] - The company will proceed with further adjustments according to the rules if additional conditions for price adjustment are triggered in the future [1] Group 2: Information Disclosure - The company will fulfill its information disclosure obligations promptly in the event of any significant matters [1]